BioNexus Gene Financials
| BGLC Stock | USD 5.09 0.95 15.73% |
Understanding current and past BioNexus Gene Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of BioNexus Gene's financial statements are interrelated, with each one affecting the others. For example, an increase in BioNexus Gene's assets may result in an increase in income on the income statement.
Please note, the presentation of BioNexus Gene's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BioNexus Gene's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of BioNexus Gene's management manipulating its earnings.
BioNexus Gene Stock Summary
BioNexus Gene competes with Blue Biofuels, BioMark Diagnostics, Spectral Med, Microbix Biosystems, and Nocopi Technologies. BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on developing and commercializing molecular diagnostic tests for the early detection of diseases and personalized health management primarily in Malaysia. BioNexus Gene Lab Corporation was incorporated in 2017 and is based in Kuala Lumpur, Malaysia with an additional office in Sheridan, Wyoming. Bionexus Gene operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 27 people.Specialization | Basic Materials, Specialty Chemicals |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 090628207 090628108 090628306 |
| Location | Malaysia |
| Business Address | Menara UOA Bangsar, |
| Sector | Chemicals |
| Industry | Materials |
| Benchmark | Dow Jones Industrial |
| Website | www.bionexusgenelab.com |
| Phone | 60 1 307 241 6898 |
| Currency | USD - US Dollar |
BioNexus Gene Key Financial Ratios
BioNexus Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BioNexus Gene's current stock value. Our valuation model uses many indicators to compare BioNexus Gene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioNexus Gene competition to find correlations between indicators driving BioNexus Gene's intrinsic value. More Info.BioNexus Gene Lab is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioNexus Gene's earnings, one of the primary drivers of an investment's value.BioNexus Gene Lab Systematic Risk
BioNexus Gene's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. BioNexus Gene volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on BioNexus Gene Lab correlated with the market. If Beta is less than 0 BioNexus Gene generally moves in the opposite direction as compared to the market. If BioNexus Gene Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one BioNexus Gene Lab is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of BioNexus Gene is generally in the same direction as the market. If Beta > 1 BioNexus Gene moves generally in the same direction as, but more than the movement of the benchmark.
About BioNexus Gene Financials
What exactly are BioNexus Gene Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include BioNexus Gene's income statement, its balance sheet, and the statement of cash flows. Potential BioNexus Gene investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although BioNexus Gene investors may use each financial statement separately, they are all related. The changes in BioNexus Gene's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on BioNexus Gene's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.BioNexus Gene July 13, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of BioNexus Gene help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of BioNexus Gene Lab. We use our internally-developed statistical techniques to arrive at the intrinsic value of BioNexus Gene Lab based on widely used predictive technical indicators. In general, we focus on analyzing BioNexus Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build BioNexus Gene's daily price indicators and compare them against related drivers.
| Downside Deviation | 9.27 | |||
| Information Ratio | 0.1042 | |||
| Maximum Drawdown | 301.65 | |||
| Value At Risk | (13.46) | |||
| Potential Upside | 14.98 |
Complementary Tools for BioNexus Stock analysis
When running BioNexus Gene's price analysis, check to measure BioNexus Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNexus Gene is operating at the current time. Most of BioNexus Gene's value examination focuses on studying past and present price action to predict the probability of BioNexus Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNexus Gene's price. Additionally, you may evaluate how the addition of BioNexus Gene to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |